Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
Key facts
- Where
- Copenhagen, DenmarkSee the site
Where in Denmark
- Rigshospitalet (Copenhagen University Hospital)Copenhagen, DenmarkNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NHS Greater Glasgow and Clyde
- Trial code
- NCT05919342
- Record updated
- 4 August 2023
- Original description
This is an international prospective, multicentre, unblinded, randomised-controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients.Read full original descriptionShow less
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY
This is an international prospective, multicentre, unblinded, randomised-controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients.
Inclusion: Male or female ≥40 years of age; Informed consent; Two or more of the following risk factors for heart failure:; Coronary artery disease (either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis of an epicardial coronary artery [50% left main stem or >70% left anterior descending, circumflex or right coronary artery]); An established diagnosis of diabetes (type 1 or type 2); Persistent or permanent atrial fibrillation (not paroxysmal atrial fibrillation); Previous ischemic or embolic stroke; Peripheral arterial disease (previous surgical or percutaneous revascularisation or a documented stenosis greater than 50% of a major peripheral arterial vessel); Chronic kidney disease (defined as an estimated glomerular filtration rate <60mL/min/1.73m2 or eGFR 60-90mL/min/1.73m2 and UACR >300mg/g); Regular loop diuretic use (any dose at any dosing interval) for >30 days; COPD (evidenced by one of the following: PFTs showing airway obstruction, diagnosis by respiratory physician, CT scan reporting presence of emphysema or treatment with national guideline advocated COPD therapy).
Exclusion: Previous documented diagnosis of heart failure; Current renal replacement therapy; Inability to give informed consent e.g., due to significant cognitive impairment; Anyone who, in the investigators' opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period.